Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis

Treatments in Endocrinology

Volumn 4, Issue 4, 2005, Pages 245-251

  Rackoff, Paula J ^a,b   Sebba, Anthony ^c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE REMODELING; BONE TURNOVER; CELL ACTIVITY; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS ULCER; FLU LIKE SYNDROME; FRACTURE REDUCTION; GASTROESOPHAGEAL REFLUX; HIP FRACTURE; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STOMACH ULCER; UNITED STATES; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; ALENDRONATE; BONE RESORPTION; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 23744450505     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200504040-00005     Document Type: Review

References (49)

1. Tsuchimoto M, Avuma Y, Higuchi O, et al. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 1994; 66: 25-33
2. Sahini M, Guenther H, Fleisch H, et al. Bisphosphonates act on rat bone resorption through mediation of osteoblasts. J Clin Invest 1993; 91: 2004-11
3. Niskikawa M, Akatsu T, Katayama Y, et al. Bisphosphonates act on osteoblastic cells and inhibit formation in mouse marrow cultures. Bone 1996; 18: 9-14
4. Van Breek ER, Lawick CW, Ebetino FH, et al. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships. Bone 1999; 25 (3): 437-42
5. Rogers MJ, Watts DJ, Russell RGG, et al. Overview of bisphosphonates. Cancer 1997; 80: 1652-69
6. Rogers MJ, Ji X, Russell RGG, et al. Incorporation of bisphosphonates by the cellular slime mold Dictyostelium discoideum. Biochem J 1994; 303: 303-11
7. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 1999; 9 Suppl. 2: S66-80
8. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1989; 83: 1930-5
9. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9
10. Cranney A, Guyatt A, Krolicki M, et al. A meta-analysis of etidronate for the treatment of osteoporosis. Osteoporos Int 2001; 12: 140-51
11. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-43
12. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41
13. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density, but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82
14. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000; 85 (11): 4118-24
15. Balema R, Toolan BC, Shea M, et al. The effects of 2-year treatment with amino-bisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993; 92: 2577-86
16. Seedor JG, Quartuccio HA, Thompson DD. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res 1991; 6 (4): 339-46
17. Schnitzer PJ. Update on alendronate for osteoporosis: once-weekly dosing. Expert Opin Pharmacother 2001; 9: 1461-72
18. Greenspan SL, Bone III G, Schnitzer TJ, et al. The Alendronate Once-Weekly Study Group: two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17 (11): 1988-96
19. Hochberg MC, Greenspan S, Wasnich R, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87 (4): 1586-92
20. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000; 85 (1): 231-6
21. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis: Fracture Intervention Trial research group. Arthritis Rheum 1999; 42 (6): 1246-54
22. Kendler DI, Wai Chee Kung A, El-Hajj Fuleiman G. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48: 243-51
23. Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995; 58 (3): 288-98
24. Delmas PD, Confavreux E, Genolet G, et al. Can alendronate be taken before lunch or dinner? A randomized trial in osteoporotic women [poster]. Osteoporosis Int 2000; 11 (Suppl 2.): S208
25. Khan SA, Kanis JA, Vasikaran S, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997; 12 (10): 1700-7
26. Nussbaum SR, Warrell Jr RP, Rude R, et al. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. Clin Oncol 1993; 11 (8): 1618-23
27. Ramachandran C, Fleisher D. Transdermal delivery of drugs for the treatment of bone diseases. Adv Drug Deliv Rev 2000; 42 (3): 197-223
28. Dohy M, Makimo Y, Hujii T. Sodium alendronate preparation for local administration. US patent 6008, 206, 1999
29. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) study group. JAMA 1999; 282 (14): 1344-52
30. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis: Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 2000; 11 (1): 83-91
31. McClung M, Geusens P, Miller P. The effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 343 (5): 333-40
32. Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71 (2): 103-11
33. Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003; 14 (5): 437-41
34. Mitchell DY, Heise MA, Pallone KA, et al. The effect of dosing regimen on the pharmacokinetics of risedronate. Br J Clin Pharmacol 1999; 48 (4): 536-42
35. Hosking D, Adami S, Feisenberg D. Comparison of change in bone mineral density with once-weekly alendronate and daily risedronate: a randomised placebo-controlled study. Curr Med Res Opin 2003; 19 (5): 383-94
36. Hosking D, Adami S, Felsenberg D, et al. Comparison of change in bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study. Curr Med Res Opin 2003; 19 (5): 383-94
37. Cooper C, Emkey RD, McDonald RH, et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88 (10): 4609-15
38. Tanko LB, Felsenberg D, Czerwinski E, et al. Oral weekly ibandronate prevents bone loss in postmenopausal women. J Intern Med 2003; 254 (2): 159-67
39. Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003; 62 (10): 969-75
40. Charpurlat RD, Delmas PD. Review of ibandronate in the treatment of osteoporosis. Exp Opin on Pharm 2003; 4 (3): 391-6
41. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Managed Care 1998; 4: 1377-82
42. Brown JP, Kendler LD, McClung MR, et al. Efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71 (2): 103-11
43. Lanza FL, Huet RN, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effect of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 866-99
44. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95 (11): 3112-7
45. Peretz A, Body JJ, Dumon JC, et al. Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 1996; 25: 69-75
46. Boutsen Y, Jamart J, Esselinckx W, et al. Primary prevention of glucocorticoid induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 1997; 61: 256-71
47. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized controlled clinical trials. J Clin Oncol 2001; 19: 558-67
48. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61
49. Zojer M, Keck AV, Pecherstorfar M. Comparative tolerability of drug therapies for hypercalcemia of malignancy. Drug Saf 1999; 21: 389-406